Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.

about

Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.

Item

http://www.wikidata.org/entity/Q49818588

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Minimal residual disease detec ...... fectively than flow cytometry.

@en

Minimal residual disease detec ...... fectively than flow cytometry.

@nl

type

Item

label

Minimal residual disease detec ...... fectively than flow cytometry.

@en

Minimal residual disease detec ...... fectively than flow cytometry.

@nl

prefLabel

Minimal residual disease detec ...... fectively than flow cytometry.

@en

Minimal residual disease detec ...... fectively than flow cytometry.

@nl

P1476

Minimal residual disease detec ...... fectively than flow cytometry.

@en

P2093

Andrew Aw

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

Kevin Hoang

http://www.w3.org/2001/XMLSchema#string

Malek Faham

http://www.w3.org/2001/XMLSchema#string

Siddha Kasar

http://www.w3.org/2001/XMLSchema#string

Stacey M Fernandes

http://www.w3.org/2001/XMLSchema#string

P2860

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

P304

1-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1397664

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29164966

http://www.w3.org/2001/XMLSchema#string